Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;10(Suppl 2):S293-S297.
doi: 10.21037/jtd.2017.10.165.

The role of intracavitary therapies in the treatment of malignant pleural mesothelioma

Pietro Bertoglio  1 , Vittorio Aprile  2 , Marcello Carlo Ambrogi  2 , Alfredo Mussi  2 , Marco Lucchi  2
Affiliations
Review

The role of intracavitary therapies in the treatment of malignant pleural mesothelioma

Pietro Bertoglio et al. J Thorac Dis. 2018 Jan.

Abstract

Surgery is one of the steps of multimodality approach for the treatment of MPM. Due to anatomical features, microscopically radical (R0) resection is never possible and a Macroscopic Complete Resection (R1) is considered the target for mesothelioma surgeons. Recently, intracavitary therapies have been described with the aim of extending the loco-regional effect of surgery. Different agents might be administered intrapleurally: chemotherapy drugs are the most widely used, but also photodynamic therapy (PDT) showed to lead to satisfactory long-term outcomes; furthermore, immunotherapies and gene therapies have been also reported. Despite promising results, no high-quality evidences are currently available and controlled randomized trials are required to establish the exact role of intracavitary therapies and to standardize the technique.

Keywords: Malignant pleural mesothelioma (MPM); intracavitary therapy; multimodality treatment; surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Bertoglio P, Waller DA. The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence. Expert Rev Respir Med 2016;10:663-72. 10.1586/17476348.2016.1171147 - DOI - PubMed
    1. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72. 10.1016/S1470-2045(11)70149-8 - DOI - PMC - PubMed
    1. Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v31-9. 10.1093/annonc/mdv199 - DOI - PubMed
    1. Bertoglio P, Fanucchi O, Ricciardi S, et al. Chest wall resection for mesothelioma recurrence after surgery. Asian Cardiovasc Thorac Ann 2016;24:893-5. 10.1177/0218492316674861 - DOI - PubMed
    1. Flores RM. Pleurectomy decortication for mesothelioma: The procedure of choice when possible. J Thorac Cardiovasc Surg 2016;151:310-2. 10.1016/j.jtcvs.2015.10.036 - DOI - PubMed

LinkOut - more resources